How healthcare tech is reshaping connected medical devices in 2026
The 2026 shift in healthcare tech
Healthcare tech in medical devices is no longer mainly about adding sensors, apps or cloud dashboards. In 2026, the bigger shift is toward connected systems that can demonstrate safety, data integrity, cybersecurity, interoperability and clinical usefulness throughout the product lifecycle. For medical device companies, hospitals and digital health teams, product value now depends as much on governance and evidence as on technical capability.
AI-enabled functions, remote monitoring, software updates and device-to-EHR data exchange can improve care workflows. They also create responsibilities around validation, bias monitoring, access control and post-market oversight. Readers following healthcare technology should watch a clear convergence among regulators, standards bodies and care providers: connected devices must be manageable, explainable and secure after deployment, not just impressive at launch.
From standalone devices to connected care systems
The most useful healthcare tech is increasingly system-level technology. A connected blood pressure monitor, infusion pump, imaging algorithm or wearable sensor is not valuable simply because it captures data. It becomes valuable when the data is accurate enough for the clinical context, transmitted securely, interpreted appropriately and integrated into workflows where clinicians can act on it.
That is why connected medical devices should be evaluated as part of a care ecosystem rather than as isolated products. The U.S. Centers for Medicare & Medicaid Services describes remote patient monitoring as patient-collected health data, such as blood pressure, weight or glucose levels, transmitted through a connected medical device to a healthcare provider. The definition points to the operational chain behind the device: patient use, device performance, data transmission, clinician review and care response. (cms.gov)
The FDA makes a similar point in its digital health work. Its December 2023 final guidance on digital health technologies for remote data acquisition in clinical investigations focuses on whether remotely collected data are fit for their intended purpose, including verification, validation, usability and data integrity considerations. For device makers, the practical lesson is that a sensor or software function should be judged by the reliability of the end-to-end evidence it creates, not only by whether it can technically collect a measurement. (fda.gov)
AI-enabled medical devices are moving into lifecycle governance
AI is one of the clearest examples of healthcare tech becoming a lifecycle issue. The FDA maintains an AI-Enabled Medical Device List for devices authorized for marketing in the United States. The list includes devices with 2026 final decision dates and is intended to improve transparency for innovators, providers and patients. The FDA also notes that the list is not a comprehensive inventory of every AI-enabled device. (fda.gov)
The practical implication is that AI-enabled device adoption should not stop at authorization status. Buyers and clinical teams need to understand the intended use, data inputs, performance limits, user instructions and update pathway. A model trained for one patient population, imaging protocol or clinical environment may not perform identically in another. That does not make AI unsafe by default, but it does mean governance must be specific to the use case.
Model changes need a pre-planned route
One important regulatory development is the FDA final guidance dated August 18, 2025, on predetermined change control plans for AI-enabled device software functions. In plain language, this matters because some AI device software may need controlled updates after clearance or approval. A credible change plan helps define what may change, how changes will be implemented and how safety and effectiveness will be maintained. (fda.gov)
For device teams, this changes product planning. Data science, clinical affairs, regulatory affairs, quality management and cybersecurity cannot operate as separate tracks. If the product roadmap includes model refinement, new input data, additional indications or workflow changes, those assumptions should be reflected in design controls and post-market monitoring plans.
Transparency is becoming part of clinical trust
AI transparency is also expanding beyond the device manufacturer. The Office of the National Coordinator for Health Information Technology says its HTI-1 final rule updates certification criteria for health IT and includes transparency requirements for AI and other predictive algorithms in certified health IT. The rule also sets USCDI Version 3 as the new baseline standard in the ONC Health IT Certification Program as of January 1, 2026. (healthit.gov)
That matters for medical devices because many device outputs eventually flow into EHRs, clinical decision support tools or analytics systems. Even when a device is well validated, a poor handoff into clinical software can weaken accountability. In 2026, a stronger evaluation question is not only whether an algorithm works, but whether the right people can understand its role, limitations and downstream use.
Cybersecurity is now a medical device safety control
Cybersecurity has moved from an IT concern to a device safety requirement. The FDA issued final guidance on June 27, 2025, for cybersecurity in medical devices, adding recommendations related to section 524B of the Federal Food, Drug, and Cosmetic Act and superseding the 2023 version of the same guidance. The FDA also states that internet-connected, network-connected and device-connected features can improve care but increase cybersecurity risk. (fda.gov)
For healthcare organizations, the risk is not theoretical. HHS OCR reported in its December 2024 HIPAA Security Rule proposed rule materials that large breach reports increased from 2018 to 2023, and that 2023 involved more than 167 million individuals affected by large breaches. HHS also stated that the current HIPAA Security Rule remains in effect while rulemaking continues. (hhs.gov)
In practice, connected devices should be assessed for security architecture, authentication, encryption, logging, vulnerability disclosure, software bill of materials practices, patch timelines and incident response coordination. The strongest products make these controls operationally visible. A hospital biomedical engineering team or security team should not have to guess which software version is deployed, which network ports are required or how quickly a critical vulnerability can be remediated.
Standards reinforce this lifecycle approach. IEC 81001-5-1:2021 focuses on security activities in the health software lifecycle and aims to increase cybersecurity by defining activities and tasks across lifecycle processes. For device developers, aligning software development, risk management and security engineering early is usually more practical than trying to retrofit controls shortly before submission or deployment. (iso.org) See also: clinical equipment.
Interoperability and data quality decide whether devices scale
Many healthcare tech projects struggle not because the device is technically weak, but because the data cannot be used consistently. Common problems include mismatched units, missing timestamps, weak patient identity matching, non-standard terminology, alert fatigue and data flows that do not fit clinical responsibility. These issues are especially important for remote monitoring, AI triage, imaging AI and device-generated data in chronic disease management.
Interoperability should be treated as a clinical design issue. If a device sends data into an EHR without context, clinicians may ignore it. If the device generates too many alerts, teams may override or disable them. If data quality differs by patient group, age, skin tone, language, device placement or home connectivity, the product can unintentionally widen performance gaps.
This is also where global regulation is moving. The European Commission says the EU AI Act entered into force on August 1, 2024 and became applicable on August 2, 2026, with exceptions and transition periods, including extended timelines for certain high-risk AI systems embedded in regulated products. The Commission also describes AI-based software intended for medical purposes as subject to high-risk requirements such as risk mitigation, high-quality datasets, clear user information and human oversight. (digital-strategy.ec.europa.eu)
For companies selling across regions, the operational message is clear: healthcare tech strategy should not be built around the lightest possible documentation. A better approach is to develop reusable evidence, risk files, data governance records and monitoring processes that can support different regulatory and customer expectations.
What device teams and providers should evaluate
The following comparison gives a practical way to assess healthcare tech in connected medical devices. It is not a regulatory checklist, but it can help teams ask stronger questions before procurement, development or deployment.
| Area | What to evaluate | Why it matters |
|---|---|---|
| Clinical purpose | Intended use, user population, workflow role and limits of use | Prevents overreliance on technology outside the context where it was evaluated |
| AI governance | Training data, validation approach, change control plan and performance monitoring | Supports safe use when models, data or clinical settings change |
| Cybersecurity | Authentication, encryption, patching, logging, SBOM practices and incident response | Reduces risks to patient safety, device performance and protected health information |
| Interoperability | Standards support, EHR integration, terminology, timestamps and data provenance | Makes device data usable in real clinical workflows |
| Usability | Patient setup, clinician review burden, alert design and accessibility | Determines whether the device can be used correctly at scale |
| Post-market oversight | Complaint trends, cybersecurity monitoring, model drift review and update communication | Keeps performance visible after launch |
A practical checklist for healthcare tech decisions
Device manufacturers and healthcare providers can use a simple decision framework before investing heavily in connected medical device technology.
- Define the clinical decision affected by the technology. If no decision changes, the product may create data without improving care.
- Document the intended user and setting. A home-use device, emergency department tool and radiology workstation each create different risks.
- Ask how performance was validated. Look for evidence that matches the target population, workflow and measurement conditions.
- Review the update model. Software and AI features need clear rules for version control, validation, rollback and user communication.
- Evaluate cybersecurity before deployment. Security review should occur before purchase or launch, not after the device is connected to the network.
- Test workflow integration. Pilot programs should measure alert burden, data completeness, clinician response and patient adherence.
- Plan post-market monitoring. Connected devices need ongoing review of safety signals, cyber vulnerabilities, complaints, performance drift and user feedback.
The larger lesson is that healthcare tech maturity is not measured by how advanced a device appears in a demo. It is measured by whether the technology can be safely operated, maintained, explained and improved in real healthcare environments.
Frequently asked questions
What does healthcare tech mean in medical devices?
In medical devices, healthcare tech refers to technologies such as connected sensors, device software, AI-enabled functions, remote monitoring platforms, interoperability tools and cybersecurity controls that support diagnosis, monitoring, treatment or care delivery. The term is broad, but in regulated medical device contexts it must be tied to intended use, clinical evidence, safety and quality processes.
Why is cybersecurity so important for connected medical devices?
Cybersecurity is important because connected devices may affect both patient data and device performance. A vulnerability can expose protected health information, disrupt care operations or interfere with how a device functions. For that reason, regulators and healthcare organizations increasingly treat cybersecurity as part of safety and lifecycle risk management.
Are AI-enabled medical devices automatically better than traditional devices?
No. AI can improve pattern recognition, workflow efficiency and decision support in some settings, but its value depends on intended use, validation quality, user understanding and monitoring after deployment. An AI-enabled device should be evaluated against the clinical problem it claims to support, not against the general reputation of AI.
What should hospitals ask before adopting new healthcare tech?
Hospitals should ask how the technology fits the clinical workflow, what evidence supports it, how data will enter existing systems, what cybersecurity controls are in place, who is responsible for monitoring outputs and how software updates will be managed. These questions help separate useful innovation from tools that add complexity without clear benefit.
What is the main trend for connected medical devices in 2026?
The main trend is accountability across the lifecycle. AI, remote monitoring, interoperability and cybersecurity are still growing, but the most important change is the expectation that device teams can show how connected technology remains safe, secure, understandable and clinically useful after it reaches real users.
